Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Oncolytic activity of ReoT3D in 9 NSCLC cell lines included in the NCI-60 cell line panel

From: Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

NSCLC Cell Line ED50 (log10 pfu/cell: mean ± SD)
NCI-H460* 2.68 ± 0.25
A549/ATCC* 2.51 ± 0.27
HOP-62* 2.56 ± 0.19
NCI-H322M > 3.30
NCI-H226 > 3.30
EKVX 2.47 ± 0.34
NCI-H23* 2.47 ± 0.15
NCI-H522 1.46 ± 0.12
HOP-92 1.96 ± 0.27
  1. ED50: 50% effective dose defined by the initial MOI (pfu/cell) to achieve 50% cell death in 48 hours after infection. Shown are mean ± SD from 3 independent experiments. *Asterisk denotes cell lines with ras gene mutation. Abbreviations: ReoT3D, reovirus type 3 Dearing; NSCLC, non-small cell lung cancer; MOI, multiplicity of infection; pfu, plaque forming units.